|Description||Ticagrelor, the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS).|
|B0084-089156||1 g||$169||In stock|
|Appearance||White to Off-White Solid|
|Synonyms||AZD-6140; AZD6140; AZD 6140; AR-C 126532XX; AR-C-126532XX; AR-C126532XX; Ticagrelor; brand name: Brilinta; Brilique; Possia|
NF 340 is a selective P2Y11 antagonist. It shows competitive antagonism against ATPγS with pIC50 values of 6.43 and 7.14 in Ca2+ and cAMP assays respectively.
MRS 2768 tetrasodium salt
MRS 2768 tetrasodium salt is a selective P2Y2 agonist (EC50 = 1.89 μM), with no affinity for human P2Y4 or P2Y6 receptors.
N6-(4-Hydroxybenzyl)adenosine, an imidazopyrimidine derivative, could be effective as an inhibitor of platelet aggregation. IC50: 6.77-141 μM.
Suramin, also called as Germanin, has been demonstrated to inhibit a large variety of enzymes including urease, hexokinase, succinic dehydrogenase, p-glucuronid...
NF 546 is a P2Y11 agonist with pEC50 value of 6.27. It can stimulate release of interleukin-8 from human monocyte-derived dendritic cells.
Cangrelor, an adenylic acid derivative, has been found to be a P2Y12 inhibitor that could be effective in some coronary artery diseases. It is under Phase I tri...
Cangrelor tetrasodium is an ATP analogue and acts as a reversible antagonist of P2Y12 receptor. Pretreatment with cangrelor significantly reduces blood clotting...
The sodium salt of Suramin which is a P2 purinergic antagonist and has been also found to have the effect in blocking the G protein binds to GPCRs so that it wa...